Entegrion, a Research Triangle=based life sciences company developing advanced blood products, has raised $4.2 million of a $5 million debt and securities offering from 59 investors, according to a regulatory filing.

Entegrion has raised $88 million from the U.S. Department of Defense to develop blood products such as freeze-dried platelets for emergency treatment of wounded soldiers and dehydrated plasma.

The platelets product, called Stasix was slated for human testing this year. Platelets are the blood component that enables clotting. Fresh platelets only last about a week, while Entegrion’s Stasix could be stored up to three years, according to the company.

The company received a $44.7 million four-year grant from the DOD to work on the dehydrated blood product, Resusix, in 2011.In 2013 it inked a deal with Kedrion Melville Inc.as a strategic investor to commercialize Resusix.

Under development for 12 years, Stasix is not expected to be approved for use until 2020.

Entegrion spun out of the University of North Carolina at Chapel Hill in 2002 as Hemocellular Therapeutics, a company that initially focused on developing Stasix.

The company, which later changed its name to Entegrion, shifted its attention for a time to a bandage that promotes clotting because that product could be commercialized more quickly.

The Stasilon bandage, made from a proprietary weave of bamboo and glass fibers, received Food and Drug Administration clearance in 2007. In April of 2011, Entegrion announced a licensing deal with Chicago company Beeken BioMedical, to market the bandage;

The company disclosed the debt offering in a filing with the US Securities and Exchange Commission.